“American Hustle” meets “The Wolf of Wall Street”

,

 

“American Hustle” meets “The Wolf of Wall Street”

 

Citron Exposes the Fraud, Collusion, and Deception that brought Textura (NYSE:TXTR) to Wall Street

For anyone who is disgusted with the abuses of Wall Street — this story is for you.  True value of the stock is less than $4 a share … AT BEST.

 

Wall Street has been sold on Textura Corp. (NYSE:TXTR) as a hot enterprise software company, rapidly consolidating the construction industry with a purported “SaaS” platform.  Sound good? 

The gap between fiction and reality couldn’t be any wider.   Equity bubble for enterprise software SaaS stocks?  Sure, but this one is so much worse…..  

Jim Chanos is fond of defining the potential for short candidates as "Fads, Frauds, and Failures".   Its rare that you find all three in one package.  

Citron encourages all readers to scrutinize the supporting links and decide for yourself: 

For the full story you won't read anywhere else, Click Here:

      (As always, you download the PDF at this link, then right-click to open all the story links locally) 

Questcor in Cover-Up Mode: Deleting Evidence from its Website … BUT Citron Finds the Smoking Gun and Presents it Here for the Federal Trade Commission. Investors please don’t read further — you might find something you don’t like.

,

Over the coming months, Citron Research will release a series of articles on Questcor (NASDAQ:QCOR) intended to shed light on probable issues of interest to the multi-pronged investigation underway by multiple regulatory agencies into numerous aspects of Questcor’s business strategy that political correct-speak would deem “legally challenged”.  These articles will dig deeper into topics such as:

·         The Chronic Disease Fund, and the role it plays in contributing to Questcor’s revenues

·         Medicare billing (it is very dangerous to participate in a scheme to defraud the Federal Government)

·         Insurance reimbursement coding for Acthar

Meanwhile, today’s question is whether Questcor’s Synacthen acquisition is anti-competitive.  The points raised in Citron’s article last week are relevant to the FTC’s inquiry, demonstrating Questcor’s intent to suppress competition by acquiring Synacthen is exposed by their own sell-side analysts.

We are sure that Questcor will now try to posture to the FTC that Synacthen is a completely different drug, arguing that while it has similarities, it cannot be regarded as a replacement for HP Acthar Gel.  This piece of evidence presented below is for the FTC, so shareholders please cover your eyes.  

For the full story you won't find anywhere else, click here!

( Citron as always recommends downloading the PDF for local viewing, and clicking on the links.)